Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.48 |
| ▸ | CCKAR | P32238 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025637 | 0.90 | CNR1 (0.53) | CNR1CCKARCNR2 | |
| SCHEMBL6024749 | 0.85 | CNR1 (0.47) | CNR1CCKARCA12CA1CA2 | |
| SCHEMBL6025648 | 0.81 | CNR1 (0.56) | CNR1CCKARCNR2 | |
| SCHEMBL6807596 | 0.81 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL5111599 | 0.81 | CNR1 (0.54) | CNR1CNR2TACR1CA12CA1 | |
| SCHEMBL6808103 | 0.80 | CNR1 (0.51) | CNR1CCKARCNR2 | |
| SCHEMBL6808358 | 0.80 | CNR1 (0.48) | CNR1CCKARCNR2 | |
| SCHEMBL6026092 | 0.79 | CNR1 (0.56) | CNR1CCKAR | |
| SCHEMBL6025823 | 0.79 | CNR1 (0.56) | CNR1CCKARCNR2 | |
| SCHEMBL5105879 | 0.79 | CNR1 (0.54) | CNR1CNR2TACR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| EP-1638570-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004110453-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CCKAR 54/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.